Clinical trial
Clinical Trial Comparing the Effectiveness of Cefixime Versus Penicillin G for Treatment of Early Syphilis
Name
HS-21-00288
Description
This study aims to evaluate the efficacy of cefixime compared to benzathine penicillin G in the treatment of syphilis.
Trial arms
Trial start
2021-06-20
Estimated PCD
2024-07-01
Trial end
2025-03-01
Status
Recruiting
Phase
Early phase I
Treatment
Cefixime 400mg
Oral cefixime 400 mg, one capsule, twice a day for 10 days
Arms:
Cefixime
Other names:
supprax
benzathine penicillin
Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
Arms:
Benzathine Penicillin G
Other names:
bicillin
Size
400
Primary endpoint
Response to treatment
6 months
Eligibility criteria
Inclusion Criteria:
* Diagnosed cases of primary, secondary, or early latent syphilis with RPR titer ≥1:8 within 3 weeks prior to enrollment
* 18 years of age or older
* Able to provide informed consent
* Individuals with HIV infection must be on treatment for HIV infection and virologically suppressed (viral load \<200 copies/mL) or have a CD4 count ≥ 350 cells/mm3 according to most recent labs before study enrollment
Exclusion Criteria:
* Pregnancy or a positive pregnancy test on the day of enrollment
* Patients showing signs and symptoms of neurosyphilis
* Serofast RPR titer, defined as persistently positive RPR titer without more than 4-fold (2-titer level) change for 12 months or greater
* Recent (within the past 7 days) or concomitant antimicrobial therapy with activity against syphilis, namely azithromycin, doxycycline, ceftriaxone, or other beta-lactam antibiotics (e.g. amoxicillin)
* Individuals with HIV infection who report HIV treatment interruption for more than 4 weeks since their most recent viral load or CD4 test
* Self-reported allergy to cephalosporins or penicillin
* Unwilling or unable to attend follow-up visits
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 400, 'type': 'ESTIMATED'}}
Updated at
2023-12-14
1 organization
2 products
2 indications
Organization
University of Southern CaliforniaProduct
CefiximeIndication
SyphilisIndication
HIVProduct
Benzathine Penicillin